The authors comment on the study of satricabtagene autoleucel (satri-cel), a CLDN18.2-specific CAR T-cell therapy, which represents an important advance in the treatment of adenocarcinoma of the stomach and gastroesophageal junction. They point out that satri-cel targets the claudin-18.2 (CLDN18.2) isoform, which is a therapeutic target in these tumors. However, they note that the method of selecting patients according to biomarkers, especially according to CLDN18.2 expression, requires more careful consideration. The debate centers on how to define CLDN18.2 "positivity" for inclusion in treatment. The authors suggest that the currently used CLDN18.2 expression criteria may not be optimal for all patients. They highlight the need to better understand the relationship between CLDN18.2 expression level and the clinical benefit of such targeted therapy. The aim of the correspondence is therefore to reevaluate the role of CLDN18.2 as a selection criterion in gastric cancer therapy.